Philip Leung
Partner,
Acerca de Philip
Experiencia
Phil Leung is the leader of our Asia-Pacific Mergers & Acquisitions practice and heads up the firm's Greater China Healthcare & Life Sciences practice. He is also an active contributor to Bain's Consumer Products, Retail and Financial Services practices.
Phil is a trusted advisor to a wide range of multinational and local companies. Since joining Bain in 1996, he has worked extensively on growth strategy, transformation programs, M&A and joint ventures in Greater China and throughout Asia-Pacific. In addition to his work with clients, Phil has also led the internal development of Bain's perspectives on mergers and acquisitions, including a global study on joint ventures.
Phil has authored many articles published in international and local media outlets and his views on the M&A landscape in Asia have been widely quoted.
Phil earned his MBA from Harvard University and graduated with an undergraduate degree in business administration, with highest honors, from University of California at Berkeley.
Recent Insights
- “Overseas Ambition: Asia-Pacific Consumer Products Companies Use M&A to Accelerate Growth,” Brief, mayo 25, 2023
- “China Needs More Women in Executive Leadership,” Report, marzo 07, 2023
- “How M&A and Divestitures Helped Asia’s Conglomerates,” M&A Report, febrero 16, 2021, Report
- “Learning from Japan’s Disappointing M&A Boom,” Brief, abril 15, 2020
- “Philip Leung: China Outbound M&A ,” Video, diciembre 19, 2018
In the News
- “Cross-border M&A crucial for Asia Pacific consumer products companies’ growth ,” Press release, mayo 30, 2023
- “Foreign asset managers are eyeing China’s vast pool of savings,” The Economist, junio 10, 2021, Private Equity
- “Foreign asset managers are eyeing China’s vast pool of savings,” The Economist, junio 08, 2021, Private Equity
- “Chinese firms may face more competition for overseas deals,” South China Morning Post, octubre 11, 2018
- “China FDA's Sovaldi nod could usher in more fast track approvals,” S&P Global, septiembre 29, 2017, Pharmaceuticals